MOESM1 of The addition of vildagliptin to metformin prevents the elevation of interleukin 1ß in patients with type 2 diabetes and coronary artery disease: a prospective, randomized, open-label study
Additional file 1: Table S1. Showing the percentage change {Δ% = [(value after treatment - baseline value)/baseline value * 100]} in each group of patients after 12 weeks of treatment
